Drugs / CMV pp65 peptide
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00499577 | Dec 2006 → Feb 2009 | plasma cell myeloma | University of Maryland Greenebaum Cancer Center | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CMV pp65 peptide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00499577 ↗ |
| Modality | Peptide | “CMV pp65 peptide” NCT00499577 ↗ |
| Route | Intramuscular | “Given intramuscularly” NCT00499577 ↗ |